Citadel Advisors’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Citadel Advisors’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-17,000	Closed	-$594K	–	15899
2024 Q1	$594K	Buy	17,000 +500	+3%	+$18.2K	﹤0.01%	7996
2023 Q4	$627K	Buy	16,500 +15,300	+1,275%	+$328K	﹤0.01%	7619
2023 Q3	$22K	Sell	1,200 -3,900	-76%	-$81.6K	﹤0.01%	12552
2023 Q2	$132K	Buy	5,100 +200	+4%	+$4.67K	﹤0.01%	10518
2023 Q1	$92.5K	Sell	4,900 -2,600	-35%	-$60.5K	﹤0.01%	11375
2022 Q4	$185K	Sell	7,500 -26,200	-78%	-$770K	﹤0.01%	10268
2022 Q3	$605K	Buy	+33,700	New	+$608K	﹤0.01%	8047

Other funds holding INBX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Citadel Advisors's INBX Position: Q2 2024 in Review

Citadel Advisors sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2024, closing a stake of 1,204,252 shares — an estimated $42.1M sold.

Citadel Advisors first reported a position in INBX in Q4 2021 and held it in 10 quarters. The position peaked at $42.1M in Q1 2024. 2 funds tracked by Wall St. Rank hold INBX as of Q2 2024.

Citadel Advisors reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Citadel Advisors sold 1,204,252 Inhibrx, Inc. Common Stock shares in Q2 2024, an estimated $42.1M.
Citadel Advisors first reported a position in Inhibrx, Inc. Common Stock in Q4 2021 and held it in 10 quarters.
Citadel Advisors's Inhibrx, Inc. Common Stock position peaked at $42.1M in Q1 2024.
2 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2024.

Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.